WeVote
Log In

Bill

Bill

A 8818

Permits certain out-of-state clinical laboratories to accept specimens from New York when there are no proper labs within the state

2025 Regular Session Introduced by Josh Jensen

Permits eligible out-of-state clinical labs to accept New York specimens when no proper NY labs exist, with state oversight to ensure quality, reporting, and safety.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 8818

Summary: New York Assembly Bill A 8818

Overview

  • Bill Number: A 8818
  • Title: Permits certain out-of-state clinical laboratories to accept specimens from New York when there are no proper labs within the state
  • Status: REFERRED TO HEALTH (Committee: Health)
  • Introduced: June 9, 2025
  • Sponsor: Josh Jensen (primary)

Purpose and Intent

Based on the bill’s title, A 8818 aims to create a pathway for certain out-of-state clinical laboratories to accept specimens from New York in situations where there are no suitable or “proper” laboratories operating within New York State. The goal appears to be to ensure access to necessary laboratory testing when local NY facilities are unavailable or unable to process specimens.

Key Provisions (as indicated by the bill’s title)

  • The bill would authorize or permit eligible out-of-state clinical laboratories to receive and process specimens sent from New York patients or health care providers.
  • Eligibility criteria would determine which out-of-state laboratories may participate and under what circumstances they may accept NY specimens (specifically when no proper NY labs are available). The exact criteria, scope, and procedural requirements would be defined in the bill’s text.
  • The measure would likely establish oversight or regulatory conditions to govern such cross-jurisdiction specimen testing, potentially including standards for quality, reporting, and recordkeeping. (Note: specific provisions are not provided in the summary.)

Important: The full text is not included here, so exact definitions, criteria, and operational rules are not available. The above reflects the intent suggested by the title.

Affected Parties

  • New York patients and health care providers who require clinical laboratory testing and may lack access to suitable NY-based labs.
  • Out-of-state clinical laboratories that would participate under the bill’s criteria.
  • New York Department of Health (or equivalent state regulatory body), which would oversee and regulate the arrangement.
  • In-state NY laboratories may be affected indirectly through changes in patient referral patterns, capacity, and competition.

Procedural and Timeline Aspects

  • The bill has been referred to the Health Committee, indicating initial review, potential hearings, and consideration of amendments.
  • Introductions occurred on June 9, 2025. There is no publicly listed subsequent action beyond the June 9th committee referral in the provided information.
  • If advanced, the bill would move through additional committee stages, potential floor votes, and, if passed, become law (subject to the legislative process and possible gubernatorial action).

Potential Impacts and Considerations

  • Access to Testing: Could improve access when NY lacks suitable labs, reducing delays for patient care.
  • Quality and Oversight: Requires clear standards to ensure testing quality, specimen integrity, and timely reporting across state lines.
  • Cost and Efficiency: May affect cost structures, reimbursement, and turnaround times; could influence the utilization of in-state vs. out-of-state labs.
  • Regulatory Coordination: Implies cross-state regulatory considerations, including licensure, accreditation, and compliance with NY requirements.
  • Impact on In-State Labs: Could alter market dynamics for NY laboratories, depending on eligibility and capacity.

Next Steps for Interested Parties

  • Monitor committee actions and any proposed amendments in the Health Committee.
  • Review the full text of A 8818 when available to understand precise definitions, eligibility criteria, reporting requirements, and enforcement mechanisms.
  • Consider how the bill interacts with existing NY laboratory licensing, patient safety rules, and reimbursement policies.

Note: The current summary is based on the bill title and stated status. Final provisions may differ once the full text is released.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.